The Priority Review

Tag

RC118

1 story

  1. Clinical trials

    RemeGen registers Phase II/III study of RC118 plus RC148 for claudin 18.2-positive gastric cancer

    The study, led by RemeGen Co., Ltd., plans to enroll 680 participants and plans to start in November 2026, with primary completion projected for April 30, 2030. It compares RC118/RC148 combinations to Tislelizumab plus CAPOX as first-line therapy for HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.